ArticleEndocrine2026
Early variations in plasma insulin-like peptide 5 during the oral glucose tolerance test: an exploratory study to further support the role of the proximal intestine in the regulation of food intake in obesity.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFollowing the identification of the incretin effect, the role of the enterohormones in regulating food intake and energy balance was recognized, ushering in a new era in the pharmacotherapy of metabolic diseases. A constellation of hormones is released from the gastrointestinal tract, some of them with biological functions still not completely defined. The insulin-like peptide 5 (INSL5) is a recently discovered enterohormone with basic studies proposing a role in the gut-brain axis and hunger regulation, although evidence in humans remains limited. It is primarily produced in the distal colon, but growing reports suggest that its secretion may also be regulated to a proximal level. METHODS/
resultsWe tested this hypothesis through hormone determination during an oral glucose tolerance test in a cohort of patients with severe obesity, observing an early decrease in plasma levels that overlapped with changes in blood glucose and insulin, supporting the idea that INSL5 could also represent a glucose/nutrient-responsive appetite-regulating hormone involved in food seeking.
conclusionsFar from establishing a direct role for gastric-jejunal mucosa or a gastric-colonic cross-talk after food ingestion, our results may incentivize future studies to confirm and validate these findings, and to explore INSL5 as a potential adjunctive target for obesity treatment.
Indexed as
Identifiers
41489703What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.